z-logo
open-access-imgOpen Access
Toward More Drug Like Inhibitors of Trypanosome Alternative Oxidase
Author(s) -
Ryan West,
Thomas Keith Cunningham,
Lewis E. Pennicott,
Srinivasa P. S. Rao,
Simon E. Ward
Publication year - 2018
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.7b00218
Subject(s) - african trypanosomiasis , neglected tropical diseases , natural product , alternative oxidase , trypanosoma brucei , tropical disease , drug , trypanosomiasis , biology , pharmacology , chagas disease , in vivo , drug discovery , drug development , disease , enzyme , immunology , medicine , biochemistry , microbiology and biotechnology , gene
New tools are required to ensure the adequate control of the neglected tropical disease human African trypanosomiasis. Annual reports of infection have recently fallen to fewer than 5000 cases per year; however, current therapies are hard to administer and have safety concerns and, hence, are far from ideal. Trypanosome alternative oxidase is an exciting target for controlling the infection; it is unique to the parasite, and inhibition of this enzyme with the natural product ascofuranone has shown to clear in vivo infections. We report the synthesis and associated structure activity relationships of inhibitors based upon this natural product with correlation to T. b. brucei growth inhibition in an attempt to generate molecules that possess improved physicochemical properties and potential for use as new treatments for human African trypanosomiasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom